In February 2019, Navamedic ASA completed the acquisition of 100% of the shares in Novicus Pharma AS, a pharmaceutical company focusing on OTC products for the Norwegian and Nordic market. Through this acquisition, the strong marketing and sales platform of Navamedic will be complemented with new opportunities from Novicus Pharma thereby creating a new Nordic pharmaceutical entity with multiple growth opportunities.
As part of the transaction, the three founders of Novicus Pharma, who have extensive experience from executive and professional positions in the pharma, OTC and FMCG business agreed to become key members of the Navamedic management team. Thus, Kathrine Gamborg Andreassen was appointed CEO of Navamedic, Ole Henrik Eriksen COO and BD responsible, and Astrid T Bratvedt Vice President of R&D.
On 4 August 2015, Navamedic ASA completed the acquisition of 100% of the shares in the Swedish medtech start-up company Observe Medical AB. Observe Medical develops innovative medical technology products that benefit patients and healthcare professionals. The acquisition creates a new business area for Navamedic with full ownership to the IPR for products with great global potential.
The first product, Sippi®, is a unique automated urine collection and measurement system for intensive care units, operating rooms and hospital wards. Sippi provides 24/7 digital data storage and wireless integration with the hospital’s patient data management system. The system also comprises a proprietary bacterial infection protection system called Sippcoat®.
On 4 October 2007, Navamedic ASA completed the acquisition of 100% of the shares in the Swedish pharmaceutical company Vitaflo Scandinavia AB, and takes the first step towards the creation of an international speciality pharmaceutical company.